What are the limitations of the percist 2 0?

While the percist 2 0 is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the percist 2 0 to ensure safe bedside use and optimal diagnostic accuracy.

How does the percist 2 0 compare to other Oncology scores?

The percist 2 0 is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the percist 2 0 free to use?

Yes. OpiCalc provides the percist 2 0 completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

PERCIST 2.0

Tumour Response Assessment

PET-based response assessment using SULpeak change and new FDG-avid lesions.

Percent change in SULpeak

New FDG-avid lesion

Complete metabolic response pattern

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

PET-based response assessment using SULpeak change and new FDG-avid lesions.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Percent change in SULpeak

New FDG-avid lesion

Complete metabolic response pattern

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

PET-based response assessment using SULpeak change and new FDG-avid lesions.

OpiCalc Medical Oncology ModuleTumour Response Assessment2026

CLINICAL INSIGHT

Background

Context

PERCIST 2.0 is included in the oncology module as a structured decision-support tool for tumour response assessment workflows.

No clinical reference data available.

PERCIST 2.0

Tumour Response Assessment

PET-based response assessment using SULpeak change and new FDG-avid lesions.

Percent change in SULpeak

New FDG-avid lesion

Complete metabolic response pattern

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

PET-based response assessment using SULpeak change and new FDG-avid lesions.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Percent change in SULpeak

New FDG-avid lesion

Complete metabolic response pattern

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

PET-based response assessment using SULpeak change and new FDG-avid lesions.

OpiCalc Medical Oncology ModuleTumour Response Assessment2026

CLINICAL INSIGHT

Background

Context

PERCIST 2.0 is included in the oncology module as a structured decision-support tool for tumour response assessment workflows.

No clinical reference data available.